Date: 2017-01-10
Type of information: Opening of new premises
Compound:
Company: Merck KGaA (Germany)
Therapeutic area: Technology - Services
Type agreement: opening of new premises
Action mechanism:
Disease:
Details: * On January 10, 2017, Merck KGaA announced the expansion of its end-to-end biodevelopment centers
to meet increasing customer demand for its turnkey portfolio of bioprocessing products, manufacturing capabilities and industry leading technological expertise. The expansion, which includes the opening of two new process development centers in the U.S. and China, follows the commercial success of Merck KGaA’s biodevelopment center in Martillac, France. The two new units will be located in close proximity to customers in the Shanghai and Boston metropolitan areas. Each will provide a full range of process development capabilities and services. This includes cell line development services, both upstream and downstream process development, as well as non-GMP clinical production.
Merck KGaA’s biodevelopment center in Martillac, France, is a fully operational single-use, GMP facility for manufacturing clinical stage batches. Equipped with a full suite of Merck KGaA technologies, including the 2000 liter single-use Mobius® bioreactor, Martillac offers biopharma companies a complete solution to support their clinical development programs.
Financial terms:
Latest news:
